Fulcrum Therapeutics' promising treatment for Sickle Cell Disease and their strong financial position, despite setbacks.

Learn simple, actionable steps to forecast cash flow and prepare your business for growth or challenges ahead.

Exelixis, Inc. (NASDAQ:EXEL), a biopharmaceutical company with a market capitalization of $9.4 billion focused on developing and commercializing novel therapies for cancer treatment, stands at a ...

The White House’s Office of Management and Budget sent this document to government agencies listing about 2,600 programs that were under review.

Exelixis, Inc. (NASDAQ:EXEL), a biopharmaceutical company focused on developing and commercializing novel therapies for difficult-to-treat cancers, has demonstrated resilience and growth potential in ...

We list the best spreadsheet software, to make it simple and easy to use spreadsheets using alternatives to Microsoft Excel. Spreadsheets are extremely common in the business world, and used for ...

Dollar set for losing week; sterling falls further after retail sales By Investing.com - Jan 17, 2025 Investing.com - The US dollar edged higher Friday, but was on course for a weekly loss after ...

Colonial Pipeline said it has completed repairs to a major fuel line that runs through Georgia and returned it to service Friday, four days after a “potential gasoline release” was reported in ...

Retail sales grow by 0.4% month-on-month in December, slower than expected By Investing.com - Jan 16, 2025 7 Investing.com - US retail sales increased at a slower-than-anticipated month-on-month ...

If approved, the company expects those drugs to generate peak sales between $1 billion and $3 billion each. Takeda certainly needs to pad out its pipeline given that the company’s lead product ...

NEW YORK, Jan 15 (Reuters) - Colonial Pipeline's main U.S. gasoline artery is expected to remain shut through Friday as the company continues to search for the source of a suspected leak in ...